Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background And Aims: Collusion, the practice of concealing a diagnosis or prognosis from a close relative to prevent emotional distress, is a complex issue in cancer care. This study aimed to estimate the prevalence of collusion among cancer patients and identify the associated factors, including educational status, time since diagnosis, and prognosis.

Methods: This 6-month cross-sectional study recruited 121 consenting cancer patients (aged >18 years) via convenient sampling at a tertiary care center in South India. Patients with psychiatric conditions or communication difficulties were excluded. The data were collected through qualitative interviews using a modified collusion questionnaire.

Results: The overall prevalence of collusion was 26.4%. Significant associations were found with educational status (P = 0.024), with collusion being highest among those with primary education (40.7%) and lowest in postgraduates (12.2%). Collusion was also significantly associated with time since diagnosis (P < 0.001), being 88.9% within 1 month and decreasing to 54.2% by 6 months. Caregivers frequently colluded (P < 0.001) even when the disease was considered partly curable. Among the collusion positive cases, 96.9% of the caregivers were unwilling to discuss the diagnosis and 87.5% unwilling to inform patients about the disease's course or outcome.

Conclusion: Collusion is prevalent in cancer patients, particularly among those with lower education levels and in the early postdiagnosis period. Caregivers often withhold comprehensive information, highlighting a need for improved communication strategies in oncology.

Download full-text PDF

Source
http://dx.doi.org/10.4103/aam.aam_215_25DOI Listing

Publication Analysis

Top Keywords

cancer patients
12
collusion
9
collusion cancer
8
cancer care
8
tertiary care
8
care center
8
center south
8
south india
8
prevalence collusion
8
educational status
8

Similar Publications

Objective: The cachexia index (CXI) demonstrates potential as both a diagnostic tool for cachexia and a prognostic tool for survival in cancer. However, CXI's predictive value has not been verified in cervical cancer. The purpose of this study is to investigate the prognostic value of the CXI in patients with cervical cancer treated with radiotherapy.

View Article and Find Full Text PDF

Endothelial Colony-Forming Cells (ECFCs) are recognized as key vasculogenic progenitors in humans and serve as valuable liquid biopsies for diagnosing and studying vascular disorders. In a groundbreaking study, Anceschi et al. present a novel, integrative strategy that combines ECFCs loaded with gold nanorods (AuNRs) to enhance tumor radiosensitization through localized hyperthermia.

View Article and Find Full Text PDF

ASO Practice Guidelines Series: Soft Tissue Sarcoma of the Extremities and Superficial Trunk.

Ann Surg Oncol

September 2025

Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Soft tissue sarcomas (STS) are a heterogeneous group of rare malignant tumors arising from mesenchymal tissues, with extremity and superficial trunk STS (eSTS) comprising the majority of cases. The management of localized eSTS requires a multidisciplinary approach to optimize oncologic and functional outcomes. This review outlines the natural history, diagnostic workup, and treatment principles for localized eSTS, emphasizing the role of histology-specific considerations in guiding management strategies.

View Article and Find Full Text PDF

Purpose: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), including patients with brain metastases (BrM) or leptomeningeal disease (LMD). This study assesses the efficacy and safety of sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) in MBC and impact on chemotherapy (CTX).

Methods: This is a single-center, retrospective, cohort study in adult patients with HR + , HER2-negative, or low MBC who received T-DXd and/or SG.

View Article and Find Full Text PDF